- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Volume 2013 (2013), Article ID 641687, 2 pages
Osteosarcoma: Lessons Learned and Future Avenues
1Department of Surgical Oncology, Tata Memorial Hospital, Mumbai 400012, India
2Children’s Cancer Hospital, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
3Department of Clinical Oncology, Leiden University Medical Center, Albinusdreef 2, 2300 RC Leiden, The Netherlands
Received 28 July 2013; Accepted 28 July 2013
Copyright © 2013 Ajay Puri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- S. S. Bielack, S. Smeland, J. Whelan, et al., “MAP plus maintenance pegylated interferon α-2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 “good response” randomization,” Journal of Clinical Oncology, vol. 31, Article ID LBA10504, 2013.
- A.-M. Cleton-Jansen, J. K. Anninga, I. H. Briaire-De Bruijn et al., “Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways,” British Journal of Cancer, vol. 101, no. 11, pp. 1909–1918, 2009.
- S. P. Chawla, A. P. Staddon, L. H. Baker et al., “Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas,” Journal of Clinical Oncology, vol. 30, no. 1, pp. 78–84, 2012.
- G. D. Demetri, S. P. Chawla, I. Ray-Coquard, et al., “Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus to control metastatic sarcoma in patients after benefit from prior chemotherapy,” Journal of Clinical Oncology, vol. 31, no. 19, pp. 2485–2492, 2013.